Associate Director, Omnichannel Enablement

Responsibilities

• Lead the design, implementation, and evolution of the omnichannel enablement framework and operational models
• Design and operationalize end-to-end customer journeys across personal, digital, and non-personal channels
• Partner with Brand Marketing to implement modular content strategies and AI-enabled tools for content deployment
• Translate omnichannel strategy into practical tools, playbooks, templates, and standards
• Work hands-on with brand teams during planning, campaign development, and launch preparation
• Serve as a strategic connector between Commercial Insights, Operations, and IT/Digital functions
• Define standards for personalization, audience targeting, and cross-channel measurement
• Lead enablement efforts including training, onboarding, and change management
• Establish measurement frameworks and feedback loops to drive continuous improvement
• Ensure execution aligns with compliance, legal, and regulatory requirements
• Identify and scale new omnichannel tools and emerging technologies

Requirements

• Bachelor’s degree required; MBA or equivalent preferred
• 8+ years of experience in commercial, omnichannel, digital, or marketing enablement within biotech, pharma, or life sciences
• Demonstrated experience designing and activating omnichannel journeys or content strategies in launch/growth environments
• Strong understanding of life sciences commercial ecosystems and data-driven decision making
• Experience translating strategy into execution across multiple channels
• Experience leveraging data, analytics, and AI-enabled tools to enhance customer experience
• Proven ability to influence without authority in a matrixed organization
• Strong communication, facilitation, and change leadership skills
• Ability to balance strategic thinking with hands-on implementation in fast-paced environments

About the Company

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.